Clinical Data ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis Pharmaceutical Technology48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.RespiratoryRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology 48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients. Respiratory Read full story Post navigation Previous: Remepy’s hybrid Parkinson’s therapy poised for phase 3Next: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
